The corporate venture capital arm of a global science-based company active in health, nutrition and materials makes equity investments into seed and venture stage companies generally taking less than 25% ownership. The firm makes allocations ranging from a few hundred thousand dollars to $5 million initially with additional capital held for future financing rounds. The firm is looking to make approximately 5-10 investments over the next 6-9 months with +10 being made over the next 2 years. The firm invests in companies located around the globe with a focus on the U.S., Europe and Israel.

Where it comes to Biomedical, the firm is looking for materials science companies in orthopedics and soft tissue repair. The firm also actively invests in human nutritional health, with a specific focus on companies active in personalized nutrition, and companies developing nutritional products. While the firm has invested in companies all the way from seed to PIPE, they generally invest into companies that have products in development or early stage commercialization.

The firm highly values experience in a firms management team and generally looks to take a board seat and play an active role in its portfolio companies. The firm is looking for companies that are interested in cooperation/alignment with their core businesses.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment management firm based in Tianjin, China manages multiple funds and is engaged in equity investment, asset management, merger and acquisition across several industries including healthcare. The size of investment varies depending on the deal, but the firm is investing from a 1 billion RMB fund for healthcare. The firm is currently seeking equity investment and licensing opportunities in China and the US. The firm is looking for companies with a China angle and has experience helping companies obtain CFDA approval.

Within healthcare, the firm is interested in medical devices, IVD, medical equipment, home-care products, and other healthcare-related technologies. The firm considers products that have at least completed prototype. The firm prefers products that have already obtained FDA clearance or approval, but it is happy to work with companies who are ~1 year away from FDA approval as well. In terms of indication areas, the firm is interested in diseases with large market potential in China, including oncology, reproductive health, cardiovascular diseases, and diabetes and metabolic disorders.

The firm seeks to work with experienced teams with strong sector knowledge. The firm is looking for products with a China angle and may request distribution rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Boston-based private investment group consisting of 145 early stage investors (strategics and angels) is currently looking for new opportunities in the life science space in seed to A rounds ranging from $100,000 to $4M. The group is open to reviewing opportunities from any country around the globe.

The group is open to all types of healthcare and life science companies including medical devices, therapeutics, diagnostics, healthcare equipment and laboratory instrumentation, digital health and material science. The firm looks for companies that have some proof-of-concept or validation data and at least a basic prototype prior to investment and is open to all classes of molecules and devices.

The group is looking for privately held companies with experienced management teams, the firm does not require a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life sciences-focused growth capital firm recently raised almost $1B for their new fund, which will invest broadly in the healthcare space. The firm seeks to make venture and growth stage investments ranging from $20M-$70M in the form of equity. The fund prefers to lead or co-lead most deals and may or may not seek a board seat along with an investment. The firm has a diverse team of pharmaceutical and finance professionals and seeks to add value to portfolio companies through strategic guidance and a steady flow of capital, allowing companies to focus on developing their products and executing their business plan.

The firm focuses on the following healthcare verticals: biotech/biopharma, medical devices, and life science / research tools and diagnostics. The fund is agnostic to therapeutic area and therapeutic modality, but does favor companies developing and commercializing solutions for significant unmet and under-met medical needs. As for biopharma drug companies, the fund typically likes to see at least GLP toxicology data for pre-clinical assets but ideally early safety/tolerability and biological activity/biomarker data in humans.

The firm has no strict company or management team requirements, but favors experienced/proven management teams and entrepreneurs who are highly skilled and knowledgeable in the specific area (technology and indication area) they are pursuing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life sciences venture capital fund founded in 2014 with a base in the Asia Pacific region currently manages two funds with $330 million assets under management and is actively seeking investment opportunities. On average, the size of investment is $5-25M in venture rounds. The firm prefers to act as the lead investor but is also open to co-investing. The firm looks for companies located around the globe, with a preference in the US and China. The firm is actively seeking new investment opportunities.

The firm is focused on Therapeutics and Medical Devices opportunities. The firm’s core focused therapeutic areas include oncology, immunology and CNS diseases, but is also opportunistic in other indications (modality agnostic) and willing to consider orphan indications. The firm is also interested in interventional, novel medical devices in cardiovascular, neuro-vascular diseases.

The firm prefers management team with strong scientific background and expertise, successful track records would be a plus but is not required. The firm generally takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A new venture fund, founded in 2019, based in the East Coast, is focused on investing in digital health technologies, with a secondary focus on enterprise software. The firm will consider all digital health companies, but has a particular interest in novel applications. The fund will invest between $50,000-1M in companies with a pre-money valuation of $2-12M, with some money reserved for follow-on investments. The firm will invest only in companies based in the US.

The firm is willing to consider all types of digital health technologies but is primarily focused on software and technology enabled services. The fund is most interested in products/services that address unmet needs and offer novel solutions, as opposed to those that are improving on products that already exist. For solutions that appear incremental, The firm applies a higher standard in terms of market validation and evidence of a repeatable sales process.

The firm looks to invest in companies with a pre-money valuation of no greater than 12M.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm with offices in USA and China consists of limited partners who include institutional investors from US and China. Typical equity investments range from US$5-10 million in businesses from Series A to pre-IPO and publicly traded companies. The firm is open to leading or following a syndicated round. Good Health Capital is now focusing on opportunities in North America.

The firm invests across therapeutics, medical devices, diagnostics, platform technologies, and digital health and is looking for companies that are top 3 in their niche sector. Within therapeutics, the firm prefer clinical stage projects. The firm is opportunistic in terms of disease areas including orphan indications. Within device and diagnostics, the firm prefers post-prototype products with clinical validation.

The firm may request board representation or board observership on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.